Prof Neil Johnson will be discussing the clinical trials for the newly available treatment for symptomatic uterine fibroids in New Zealand, Ryeqo. He will delve into the clinical trial results for this oral treatment containing Relugolix, a GnRH antagonist, with add-back therapy (estradiol & norethisterone acetate), including both efficacy and safety data, and longer-term outcomes. This data will be related back to clinical practice and there will be an opportunity for Q&A with the audience.

The increased risk of Caesarean section wound breakdown can be linked to a number of factors including gestational diabetes and elevated patient BMI. This education event aims to illustrate the efficacy of a hospital wide protocol integrating single use Negative Pressure Wound Therapy (sNPWT) as a preventative measure within a comprehensive care bundle.  This initiative has yielded a significant decrease in instances of Caesarean section wound breakdown, consequently enhancing patient satisfaction and overall healthcare experience.